We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
OPDIVO Bristol-Myers Squibb Australia Pty Ltd
Product name
OPDIVO
Accepted date
Oct-2024
Active ingredients
nivolumab
Proposed indication
For the treatment of advanced hepatocellular carcinoma or hepatocellular carcinoma that cannot be removed surgically.
Application type
C (new indication)
Publication date
Oct-2024